| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Heartflow, Inc.$26.72
-1 (-3.61%)
D 24Pipeline Score Tools & Services · Commercial
Market Cap
2.31 B
EPS
-1.40
P/E Ratio
-19.2 $
Value Trade
37.40 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
52.59 M
R&D Expenses
21.62 M
Operating CF
-30.10 M
Total Assets
344.02 M
Total Liabilities
58.31 M
Equity
285.72 M
D/E Ratio
12,345
10.26 %
Week
8.25 %
1 Month
33.14 %
3 Month
33.14 %
6 Month
33.14 %
5 Year
33.14 %
All Time
Cash Data
Cash Position
158.32 M
Monthly Burn
10.04 M
Runway
14.1 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
923.96 K
52 Week Range
20.13 - 41.22
% held by Insiders
26.07 %
% held by Institutions
67.57 %
Enterprise Value
2.16 B
Total Shares
85.20 M
Short %
9.48 %
Float Shares
54.61 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D24
Pipeline Score $0M
Pipeline ValueValuation Signal
1
Drugs Scored—
rNPV / MCap Top 23%
Micro Cap (rank 702 of 911)
Percentile RankHeartflow, Inc. faces pipeline headwinds (24/100), with 1 assets in development.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Heartflow Plaque Analysis | coronary artery disease | — | 2026-07-09 | over 50% of symptomatic patients with zero coronary artery calcium (CAC) harbor significant non-calcified plaque; Half of all patients presenting with a CAC score of zero were reclassified into higher-risk categories once TPV was considered; 30% of patients with CAC scores of 1-99 or 100-299 were moved to a higher-risk category with the addition of TPV; downward classification in 27% of patients with CAC scores of 1,000 or higher Read More | New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management Read More | |
Heartflow Plaque Analysis | coronary artery disease | — | 2026-07-09 | over 50% of symptomatic patients with zero coronary artery calcium (CAC) harbor significant non-calcified plaque; Half of all patients presenting with a CAC score of zero were reclassified into higher-risk categories once TPV was considered; 30% of patients with CAC scores of 1-99 or 100-299 were moved to a higher-risk category with the addition of TPV; downward classification in 27% of patients with CAC scores of 1,000 or higher Read More | New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management Read More | |
Heartflow Plaque Analysis | coronary artery disease | — | 2026-07-09 | over 50% of symptomatic patients with zero coronary artery calcium (CAC) harbor significant non-calcified plaque; Half of all patients presenting with a CAC score of zero were reclassified into higher-risk categories once TPV was considered; 30% of patients with CAC scores of 1-99 or 100-299 were moved to a higher-risk category with the addition of TPV; downward classification in 27% of patients with CAC scores of 1,000 or higher Read More | New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HTFL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HTFL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HTFL▲ +6%on this news
New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management
Heartflow, Inc. announced the presentation of new data at the SCCT 2026 Annual Scientific Meeting, highlighting the effectiveness of its AI-powered Heartflow Plaque Analysis. The data, derived from over 36,000 patients, demonstrate that traditional calcium scoring may miss significant non-calcified plaque, which Heartflow's technology can accurately detect. The newly launched Heartflow Plaque Staging tool is integrated into every analysis, allowing for precise risk stratification and improved patient management.
Read more →HTFLHeartflow Reports F irst Quarter 202 6 Financial Results and Raises Full Year 2026 Guidance SAN FRANCISCO — Ma y 1 4 , 202 6 – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for cor
Heartflow, Inc. reported its first quarter 2026 financial results, revealing a significant 41% increase in total revenue year-over-year, primarily driven by the growth of its FFRCT business. The company also raised its full year guidance, emphasizing its leadership position in AI technology for coronary artery disease. Despite the revenue growth, Heartflow experienced an increase in net operating loss to $29.5 million, indicating challenges in cost management. The overall expansion of the company's AI-driven solutions suggests positive momentum moving forward.
Read more →HTFLThe Future of Intoxication Detection May Be in Your Voice
MindBio Therapeutics is developing a novel AI-driven platform that utilizes voice analysis to detect drug and alcohol intoxication in real-time. This innovative approach aims to address the limitations of traditional testing methods, which are often invasive and slow. The company is targeting a significant market in workplace safety and substance testing, potentially transforming public health and regulatory enforcement.
Read more →HTFL▼ -5.1%on this news
Heartflow to Report First Quarter 2026 Financial Results on May 14, 2026
Heartflow, Inc. will announce its financial results for Q1 2026 on May 14, 2026, after market close. A conference call will follow at 1:30 p.m. PT to discuss these results. The company continues to enhance its AI technology for coronary artery disease, which has been adopted by numerous institutions worldwide.
Read more →HTFLHeartflow Files Patent Infringement Lawsuit Against Cleerly
Heartflow, Inc. has filed a patent infringement lawsuit against Cleerly, Inc. in Texas, claiming that Cleerly's products infringe on six of its patents. The lawsuit seeks permanent injunctive relief and damages due to unauthorized use of Heartflow's technology. Heartflow emphasizes its commitment to protecting its innovations, which have benefited over 600,000 patients worldwide.
Read more →HTFL▲ +13.1%on this news
xFEFF; Heartflow Reports Fourth Quarter and Full Year 2025 Financial Results M OUNTAIN VIEW , C alif. – March 1 8 , 202 6 – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for corona
Heartflow, Inc. reported impressive financial results for the fourth quarter and full year of 2025, with total revenue reaching $176 million, representing a 40% increase year-over-year. The company highlighted strong growth in U.S. revenue, supported by increased adoption of its Heartflow Platform, and noted improvements in gross margins. However, the net operating loss for the quarter increased compared to the previous year, amidst rising overall operating expenses. The company's guidance for 2026 remains optimistic, indicating confidence in continued growth and innovation.
Read more →HTFL▼ -16.5%on this news
Heartflow Expands GAMEFILM Registry to NBA and NHL Alumni, Precisely Measuring Heart Disease Risk in Former Professional Athletes
Heartflow, Inc. has expanded its GAMEFILM Registry to include former NBA and NHL players, building on its initial success with NFL athletes. This initiative aims to assess heart disease risk among professional athletes using advanced AI technology. The registry seeks to enroll up to 300 former players to enhance understanding of cardiovascular health in this population. Heartflow's efforts highlight the importance of proactive heart care in preventing serious health issues.
Read more →HTFLHeartflow Investor Presentation January 2026  Disclaimers Forward-Looking Statements This presentation includes express or implied forward-looking statements within the meaning of the Private Securities Litigatio
HeartFlow presented forward-looking statements concerning its business strategy, market growth, and operational expectations. The company outlined significant financial metrics, noting $162 million in revenue for the last twelve months and 41% year-over-year growth. However, it also emphasized notable risks, including reliance on its main product and uncertainties in market adoption. Despite this, HeartFlow remains optimistic about its leadership in AI technology for coronary artery disease and its potential market expansion.
Read more →HTFLHeartflow to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Heartflow, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The event will showcase Heartflow's advancements in AI technology for coronary artery disease, highlighting its impact on cardiovascular care. The presentation will be accessible live and archived on their website.
Read more →HTFLHeartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease
Heartflow, Inc. announced new analyses from the FISH&CHIPS study, showcasing the effectiveness of Heartflow FFRCTAnalysis in improving diagnostic decisions and predicting cardiovascular events in over 90,000 patients. The study demonstrated substantial cost savings and reduced unnecessary tests, highlighting the clinical and economic value of this AI-powered technology in managing coronary artery disease.
Read more →HTFLHeartflow Reports Third Quarter 2025 Financial Results Initiates Full Year 2025 Revenue Guidance of $173.0 Million to $173.5 Million Mountain View, CA
Heartflow, Inc. (Nasdaq: HTFL) reported its financial results for the third quarter of 2025, revealing a total revenue of $46.3 million, marking a 41% increase year-over-year. The company initiated full-year revenue guidance, expecting between $173.0 million and $173.5 million for 2025. Despite the positive growth, Heartflow recorded a net operating loss of $15.1 million. The increased physician interest in Heartflow's Plaque Analysis and recent commercial coverages are seen as promising signs for future growth.
Read more →Competitive Position
How HTFL ranks across every disease it competes inCompetitive Position is a premium feature
See how HTFL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial